Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:CRNX NASDAQ:NAMS NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$35.54-0.5%$36.16$23.23▼$39.95$1.12B0.65373,988 shs188,398 shsCRNXCrinetics Pharmaceuticals$40.08-0.9%$36.68$24.10▼$62.53$3.77B0.331.10 million shs1.90 million shsNAMSNewAmsterdam Pharma$36.28+3.7%$28.51$14.06▼$41.47$4.09B0.02937,252 shs1.05 million shsPRAXPraxis Precision Medicines$178.01-3.5%$60.95$26.70▼$205.89$3.77B2.62544,898 shs643,034 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+0.99%+8.61%+0.20%+11.21%-1.33%CRNXCrinetics Pharmaceuticals-5.65%-8.43%+19.90%+32.95%-32.18%NAMSNewAmsterdam Pharma-4.06%-13.47%+29.39%+49.64%+84.99%PRAXPraxis Precision Medicines-2.94%+221.59%+281.61%+217.93%+155.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$35.54-0.5%$36.16$23.23▼$39.95$1.12B0.65373,988 shs188,398 shsCRNXCrinetics Pharmaceuticals$40.08-0.9%$36.68$24.10▼$62.53$3.77B0.331.10 million shs1.90 million shsNAMSNewAmsterdam Pharma$36.28+3.7%$28.51$14.06▼$41.47$4.09B0.02937,252 shs1.05 million shsPRAXPraxis Precision Medicines$178.01-3.5%$60.95$26.70▼$205.89$3.77B2.62544,898 shs643,034 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+0.99%+8.61%+0.20%+11.21%-1.33%CRNXCrinetics Pharmaceuticals-5.65%-8.43%+19.90%+32.95%-32.18%NAMSNewAmsterdam Pharma-4.06%-13.47%+29.39%+49.64%+84.99%PRAXPraxis Precision Medicines-2.94%+221.59%+281.61%+217.93%+155.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 3.00Buy$42.3318.08% UpsideCRNXCrinetics Pharmaceuticals 2.71Moderate Buy$74.4585.03% UpsideNAMSNewAmsterdam Pharma 2.70Moderate Buy$43.2020.15% UpsidePRAXPraxis Precision Medicines 2.77Moderate Buy$222.3622.91% UpsideCurrent Analyst Ratings BreakdownLatest COLL, NAMS, PRAX, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025NAMSNewAmsterdam PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$52.0010/20/2025NAMSNewAmsterdam PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$52.0010/20/2025PRAXPraxis Precision MedicinesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$33.00 ➝ $73.0010/17/2025NAMSNewAmsterdam PharmaCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $50.0010/17/2025PRAXPraxis Precision MedicinesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$65.00 ➝ $280.0010/17/2025PRAXPraxis Precision MedicinesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$80.00 ➝ $330.0010/17/2025PRAXPraxis Precision MedicinesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.00 ➝ $360.0010/16/2025PRAXPraxis Precision MedicinesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$65.00 ➝ $300.0010/16/2025PRAXPraxis Precision MedicinesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$155.00 ➝ $350.0010/16/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $232.0010/16/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $250.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.79$12.53 per share2.86$7.10 per share5.05CRNXCrinetics Pharmaceuticals$1.04M3,644.04N/AN/A$14.29 per share2.82NAMSNewAmsterdam Pharma$45.56M88.89N/AN/A$8.20 per share4.38PRAXPraxis Precision Medicines$8.55M447.94N/AN/A$23.90 per share7.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.0434.475.96N/A5.13%97.28%13.87%11/6/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/6/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$12.29N/AN/AN/AN/A-60.07%-54.84%11/5/2025 (Estimated)Latest COLL, NAMS, PRAX, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025COLLCollegium Pharmaceutical$1.89N/AN/AN/A$191.25 millionN/A11/6/2025Q3 2025CRNXCrinetics Pharmaceuticals-$1.27N/AN/AN/A$0.39 millionN/A11/5/2025Q3 2025NAMSNewAmsterdam Pharma-$0.41N/AN/AN/A$4.54 millionN/A11/5/2025Q3 2025PRAXPraxis Precision Medicines-$3.45N/AN/AN/A$0.06 millionN/A8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million8/4/2025Q2 2025 & Study ResultPRAXPraxis Precision Medicines-$3.40-$3.31+$0.09-$3.31$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.271.181.10CRNXCrinetics PharmaceuticalsN/A17.8017.80NAMSNewAmsterdam PharmaN/A21.0821.08PRAXPraxis Precision MedicinesN/A6.316.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ACRNXCrinetics Pharmaceuticals98.51%NAMSNewAmsterdam Pharma89.89%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%CRNXCrinetics Pharmaceuticals4.60%NAMSNewAmsterdam Pharma20.84%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableCRNXCrinetics Pharmaceuticals21094.18 million89.84 millionOptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionablePRAXPraxis Precision Medicines11021.17 million20.60 millionOptionableCOLL, NAMS, PRAX, and CRNX HeadlinesRecent News About These CompaniesPraxis Precision Medicines (NASDAQ:PRAX) Shares Up 7.9% After Analyst UpgradeOctober 23 at 2:31 AM | americanbankingnews.comIs Praxis Precision Medicines Worth a Closer Look After 261.8% Surge on Trial Results?October 22 at 7:10 PM | finance.yahoo.comPraxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential TremorOctober 22 at 7:10 PM | msn.comWedbush Equities Analysts Cut Earnings Estimates for PRAXOctober 22 at 7:05 AM | marketbeat.comTD Asset Management Inc Has $2.69 Million Position in Praxis Precision Medicines, Inc. $PRAXOctober 22 at 3:37 AM | marketbeat.comPraxis Precision Medicines Updates Corporate PresentationOctober 21 at 1:39 PM | msn.comPraxis Precision Medicines (NASDAQ:PRAX) Trading 7.9% Higher Following Analyst UpgradeOctober 21 at 11:36 AM | marketbeat.comWedbush Maintains Praxis Precision Medicines (PRAX) Underperform RecommendationOctober 21 at 8:38 AM | msn.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 9.5% - Here's What HappenedOctober 20 at 4:49 PM | marketbeat.comWedbush Increases Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $73.00October 20 at 9:32 AM | marketbeat.comPraxis Precision Medicines' (PRAX) Buy Rating Reiterated at Truist FinancialOctober 20 at 2:07 AM | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $250.00October 19, 2025 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $232.00October 19, 2025 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Up Following Analyst UpgradeOctober 19, 2025 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Up After Analyst UpgradeOctober 18, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Given Buy Rating at Truist FinancialOctober 18, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Given New $232.00 Price Target at HC WainwrightOctober 18, 2025 | marketbeat.comPraxis Precision Medicines (PRAX) Stock Soars as Tremor Drug Clears Key Clinical MilestoneOctober 18, 2025 | blockonomi.comPraxis Precision Medicines (PRAX) Stock Soars as Tremor Drug Clears Key Clinical MilestoneOctober 18, 2025 | blockonomi.comGuggenheim Maintains Praxis Precision Medicines (PRAX) Buy RecommendationOctober 18, 2025 | msn.comTruist Securities Reiterates Praxis Precision Medicines (PRAX) Buy RecommendationOctober 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Bassett Furniture: Buy Now, Sit Back, and Collect DividendsBy Thomas Hughes | October 11, 2025COLL, NAMS, PRAX, and CRNX Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$35.54 -0.17 (-0.48%) Closing price 04:00 PM EasternExtended Trading$35.53 -0.01 (-0.03%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Crinetics Pharmaceuticals NASDAQ:CRNX$40.08 -0.35 (-0.87%) Closing price 04:00 PM EasternExtended Trading$39.33 -0.75 (-1.88%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.NewAmsterdam Pharma NASDAQ:NAMS$36.28 +1.28 (+3.66%) Closing price 04:00 PM EasternExtended Trading$36.28 0.00 (0.00%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Praxis Precision Medicines NASDAQ:PRAX$178.01 -6.42 (-3.48%) Closing price 04:00 PM EasternExtended Trading$177.26 -0.75 (-0.42%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
